Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Public Workshop: Innovative Systems for Delivery of Drugs and Biologics Scientific, Clinical, and Regulatory Challenges
July 8, 2003 Bethesda, Maryland
Jonathan S. Kahan Partner Hogan & Hartson L.L.P. 555 Thirteenth Street, NW Washington, DC 20004-1109 Phone: (202) 637-5794 Fax: (202) 637-5910 E-Mail: JSKAHAN@HHLAW.COM
Hogan & Hartson L.L.P.
Presentation Overview
Legal Framework for Regulation of Combination Products FDAs Historical Approach to the Regulation of Combination Products and Drug Delivery Devices The Obstacles and Challenges to Efficient Regulation of Drug Delivery Devices Consideration of New Policies and Procedures to Regulate Drug Delivery Devices
2
Legal Framework for Regulation of Combination Products and Drug Delivery Devices
Drugs
Articles Intended to Prevent, Cure, or Treat Disease Articles Intended to Affect Structure or Function of the Body (Section 201(h) of FDCA)
Devices
Same Definition As Drugs, but Devices Cannot Achieve Their Primary Purposes Through Chemical or Metabolic Action in or on the Body Devices Usually Accomplish Their Primary Purpose by Mechanical Means
Hogan & Hartson L.L.P.
Legal Framework
Biologics (Section 351, PHS Act)
A Virus, Serum, Toxin, Antitoxin, Vaccine, Blood, Blood Component or Derivative, Allergenic Product, or Analogous Product Intended for the Prevention, Treatment or Cure of Diseases or Injuries of Man
Legal Framework
Prior to 1990, Combination Products Regulated on a Case-by-Case Basis
Condoms With Nonoxynol-9 Biliary Lithotripters Used With Ursodeoxycholic Acid Transdermal Patches for Drug Delivery Antimicrobial Coated Catheters
Legal Framework
The SMDA of 1990 Sought to Add Structure to Combination Product Regulation, Including Drug Delivery Devices FDA Promulgated Procedures to Effect SMDA Under SMDA, a Lead Center Within FDA To Be Designated for Review Authority Based On Primary Mode of Action Primary Mode of Action Never Defined by Congress or FDA
Hogan & Hartson L.L.P.
Legal Framework
Definition of Combination Products (21 C.F.R. 3.2)
Comprised of Two or More Regulated Components That Are Physically, Chemically, or Otherwise Combined or Mixed and Produced As a Single Entity (e.g., Prefilled Syringes) Two or More Separate Products Packaged Together in a Single Package or As a Unit (e.g., Lumbar Puncture Kits) 7
Legal Framework
Definition of Combination Products (21 C.F.R. 3.2)
A Product Packaged Separately but Intended for Use With a Particular Approved Product Where Both Products Are Required to Achieve the Intended Use, Indication, or Effect, and the Approved Products Labeling Would Need to Be Changed Upon Approval Any Investigational Product Packaged Separately, but Intended for Use Only With Another Individually Specified Investigational Product Where Both Products Are Necessary to Achieve the Intended Use
Legal Framework
FDAs Regulatory Structure for Dealing With Drug Delivery Devices
Office of Combination Products The Center Product Jurisdiction Officers The Request for Designation The Pre-IDE/Pre-IND Meetings Coordination Between CDRH, CBER, CDER
10
Historical Regulation
The Second Generation of Drug Delivery Devices
Tobacco Products Laser Activated Drugs Drug Coated Catheters and Stents Catheters to Locally Deliver Specific Drugs Porators and New Patches The Drug Lollipop or Chewing Gum
11
Historical Regulation
The Evolving Technologies
Drug Delivery Via Chip Technologies The Closed Loop Physiological Monitor Triggering Drug Delivery Inhalation for Drug Delivery Needle-free Drug Delivery Implantable Encapsulation Technologies Nanotechnology Drug Delivery Devices
12
The Challenges and Obstacles of New Drug Delivery Technologies Many Drug Delivery Devices Are Developed By
Device Companies for Uses With Approved Drugs or Biologics Creates Challenges if the Device Allows the Drug to Be Used For:
New and Different Indications Different Mode of Delivery (e.g., I.V. vs. Topical) Different Drug Dosage/Schedule
The Challenge of Modifying the Drug Formulation to Optimize Delivery With the Device
Hogan & Hartson L.L.P.
13
What is the Regulatory Path if the Device is Designed to Deliver a Family of Drugs?
Hogan & Hartson L.L.P.
14
15
16
17
Should CDER or CBER Always Have Lead Jurisdiction of the Drug or Biologic? Does FDA Routinely Focus on the Last Thing the Product Does to Define Primary Mode of Action?
Drug delivery catheters Transdermal drug delivery The photodynamic therapy paradigm
Hogan & Hartson L.L.P.
18
19
New Approaches
Should There Always be Preference For One Approval Submission?
Is the Idea of the New NDA or NDA Supplement Along with a PMA or 510(k) for the Drug Delivery Device Outmoded and Inefficient? Does FDA Need New Legislation to Accomplish a Unitary Approval Mechanism for Drug Delivery Devices?
20
New Approaches
How Best to Define Primary Mode of Action? Factors to Consider in Defining Primary Mode of Action What is the Innovative Drive Behind the Product? What Role Does Safety and Efficacy Play in Defining Primary Mode of Action? How Will the Product be Used? Who Will Use the Product? Should the Primary Mode of Action Standard be Legislatively Replaced?
21
Conclusion
The Present System of Dual Approvals is Not Optimal The Primary Mode of Action Standard, as Presently Implemented Without Guidance, is Difficult to Apply and Interpret New FDA Guidance on Classes of Drug Delivery Devices and the Regulatory Pathways Would Be a Significant Help
The Intercenter Agreements are Outdated 22
Conclusion
Move Toward a Unitary Drug Delivery Device Approval Mechanism with Single Center Jurisdiction is Needed The OCP Should Have the Power to Oversee and Play a Significant Role in Novel Drug Delivery Device Approvals
23